Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
62°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intra-Cellular Ther
(NQ:
ITCI
)
74.83
-0.44 (-0.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intra-Cellular Ther
< Previous
1
2
3
4
5
Next >
10 Health Care Stocks Whale Activity In Today's Session
December 14, 2023
Via
Benzinga
Expert Ratings for Intra-Cellular Therapies
December 11, 2023
Via
Benzinga
Are These Biotechs Ready To Launch?
December 09, 2023
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...
Via
Talk Markets
Intra-Cellular Therapies's Earnings: A Preview
November 01, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
August 22, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
August 03, 2023
Via
Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
July 06, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 22, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 05, 2023
Via
Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
May 04, 2023
Via
Benzinga
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
July 06, 2023
Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are...
Via
Benzinga
A Preview Of Intra-Cellular Therapies's Earnings
May 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
April 20, 2023
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
March 29, 2023
Via
Benzinga
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
March 28, 2023
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
March 02, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
April 07, 2023
Via
Benzinga
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
March 29, 2023
Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday.
Via
Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 28, 2023
Gainers
Via
Benzinga
Earnings Outlook For Intra-Cellular Therapies
February 28, 2023
Via
Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
November 23, 2022
Via
Benzinga
Why Intra-Cellular Therapies Climbed Tuesday
March 28, 2023
The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.
Via
The Motley Fool
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
March 28, 2023
The company believes it may have the answer for patients with "mixed features."
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 28, 2023
Via
Benzinga
Recap: Intra-Cellular Therapies Q3 Earnings
November 03, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Intra-Cellular Therapies's Earnings: A Preview
November 02, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
September 02, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
August 22, 2022
Upgrades
Via
Benzinga
Illumina, Poshmark, Olo And Some Other Big Losers From Friday
August 15, 2022
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.